Clinical effect of Shakubactril/valsartan sodium tablets on hemodialysis patients with heart failure with mild-range ejection fraction
YAN Haiyang1,2, DONG Yi1, XIE Longhui1, LI Peiyan1, WANG Shufang1
1. the First Department of Specialty Medicine, Inner Mongolia Corps Hospital of the Chinese People's Armed Police Force, Hohhot 010010,China; 2. Brain Research Institution of Characteristics Medical Center of the Chinese People's Armed Police Forces, Tianjin 300162, China
Abstract：Objective To observe the clinical effect of Shakubactril/valsartan sodium tablets on hemodialysis (HD)patients with heart failure with mild-range ejection fraction(HFmrEF). Methods Thirty-six patients with heart failure who received treatment in the Blood purification room of Inner Mongolia Corps Hospital of the Chinese People's Armed Police Force from December 2018 to December 2021 were selected as the research objects, and the HFmrEF was first found. They were randomly divided into treatment group and control group, with 18 cases in each group. Both groups were treated with regular hemodialysis, diuretics and beta blockers. Treatment group was added with salcubactril/valsartan sodium tablets 50 mg, twice a day; The control group was added with 80 mg valsartan capsules once a day, and the treatment time of both groups was 24 weeks. After 24 weeks, the clinical efficacy, blood pressure and cardiac function indexes of the two groups were analyzed and compared. Results There was no significant difference of the clinical data and cardiac parameters between the treatment group and the control group before treatment. After treatment of 24 weeks, the total clinic effective rate[14/18(77.8%)] in the treatment group was significantly higher than that in the control group [7/18(38.9%)] and the improvement of cardiac function in the treatment group was significantly better than that in the control group,while the left ventricular ejection fraction (LVEF) in the treatment group was higher than that in the control group [(50.61±4.27)% vs. (47.50±4.09)%,t=2.232,P=0.032]; N-terminal pro-B-type natriuretic peptide (NT-pro BNP) in the treatment group was significantly lower than that in the control group [(3480.89±1308.51)pg/ml vs. (4817.72±1580.41)pg/ml,t=-2.764,P=0.009], but the cardiac parameters left ventricular end diastolic dimension (LVEDD) and left ventricular posterior wall (LVPW) were no significant difference in the two groups; LVEF, LVEDD, and NT-pro BNP were all improved significantly compared with the baseline in both groups (all P<0.05), and there was no significant difference of LVPW before and after treatment in the two groups. Conclusions Shakubactril/valsartan sodium tablets can improve cardiac function, increase LVEF and decrease NT-proBNP in patients with HFmrEF on hemodialysis.
Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study[J]. Lancet Glob Health, 2016,4(5):e307-319.
[2]
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012,379(9818):815-822.
Godeau D, Petit A, Richard I, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020,395(10225):709-733.
Wang F, Yang C, Long J, et al. Executive summary for the 2015 annual data report of?the china kidney disease network (CK-NET)[J]. Kidney Int, 2019,95(3):501-505.
Wang I K, Lu C Y, Lin C L, et al. Comparison of the risk of de novo cardiovascular disease between hemodialysis and peritoneal dialysis in patients with end-stage renal disease[J]. Int J Cardiol, 2016,218:219-224.
[10]
Jgf C, Bunting K V, Flather M D, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials[J]. Eur Heart J, 2018,39(1):26-35.
Rastogi A, Novak E, Platts A E, et al. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction[J]. Eur J Heart Fail, 2017,19(12):1597-1605.
Bavishi C, Messerli F H, Kadosh B, et al. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials[J]. Eur Heart J, 2015,36(30):1967-1973.
[15]
Burnier M. Angiotensin II type 1 receptor blockers[J]. Circulation, 2001,103(6):904-912.
Heyse A, Manhaeghe L, Mahieu E, et al. Sacubitril/valsartan in heart failure and end-stage renal insufficiency[J]. ESC Heart Fail, 2019,6(6):1331-1333.
[18]
Joseph M S, Palardy M, Bhave N M. Management of heart failure in patients with end-stage kidney disease on maintenance dialysis: a practical guide[J]. Rev Cardiovasc Med, 2020,21(1):31-39.
[19]
Lee S, Oh J, Kim H, et al. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease[J]. ESC Heart Fail, 2020,7(3):1125-1129.
Desai A S, Solomon S D, Shah A M, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial[J]. JAMA, 2019,322(11):1077-1084.
[22]
Ambrosy A P, Braunwald E, Morrow D A, et al. Angiotensin receptor-neprilysin inhibition based on history of heart?failure and use of renin-angiotensin system antagonists[J]. J Am Coll Cardiol, 2020,76(9):1034-1048.
2023, Vol. 34 
